



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2017

---

## **Spiradenocarcinoma: a comprehensive data review**

Staiger, Roxane D ; Helmchen, Birgit ; Papet, Claudia ; Mattiello, Diana ; Zingg, Urs

DOI: <https://doi.org/10.1097/DAD.0000000000000910>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-141119>

Journal Article

Published Version

Originally published at:

Staiger, Roxane D; Helmchen, Birgit; Papet, Claudia; Mattiello, Diana; Zingg, Urs (2017). Spiradenocarcinoma: a comprehensive data review. *American Journal of Dermatopathology*, 39(10):715-725.

DOI: <https://doi.org/10.1097/DAD.0000000000000910>

# Spiradenocarcinoma: A Comprehensive Data Review

Roxane D. Staiger, MD,\* Birgit Helmchen, MD,† Claudia Papet, MD,‡ Diana Mattiello, MD,§ and Urs Zingg, MD¶

**Introduction:** Spiradenocarcinomas (SCs) are rare and potentially aggressive skin adnexal tumors. Optimal treatment has not yet been established. Experiences with this carcinoma are mostly presented in case reports and few case series.

**Objective:** To generate a synopsis of published data on SC with regard to diagnostic procedures, treatment, and outcome.

**Results:** Median patient age was 60 years and sex distribution was balanced. Tumor manifestations were evenly distributed within the sweat gland carrying skin. The most commonly reported symptom was accelerated growth of a longstanding indolent lesion, typically present for more than 2 years. Metastatic spread to the lung, bone, lymph nodes, liver, kidney, and breast has been documented. For staging computed tomography (CT) and positron emission tomography-CT are recommended, especially for detection of hematogenic metastases and lymph node involvement. Clear resection margins and tumor free regional lymph nodes reduce recurrence and carcinoma related death. Although low-grade SCs were reported over 3 times more often, high-grade carcinomas show a greater likelihood for recurrence and lethal outcome.

**Conclusion:** Suspicion of an SC should lead to performance of a magnetic resonance imaging for defining tumor extent, and a fludeoxyglucose positron emission tomography-CT for detection of metastases. Radical tumor excision and resection of tumor involved regional lymph nodes are essential for a curative approach. Histopathological evaluation should involve determination of tumor differentiation grade, because high-grade carcinomas seem to have a much more aggressive behavior. Excision of distant metastases has no therapeutic value. Follow-up needs to be carried out in short intervals with frequent imaging.

\*Research Fellow, Department of Visceral- and Transplant Surgery, University Hospital of Zurich, Zurich, Switzerland; †Senior Physician, Department of Pathology, Triemli Hospital, Zurich, Switzerland; ‡Senior Physician, Department of Oncology, Limmattal Hospital, Zurich-Schlieren, Switzerland; §Senior Physician, Department of Surgery, Limmattal Hospital, Zurich-Schlieren, Switzerland; and ¶Director and Chief Physician, Department of Surgery, Limmattal Hospital, Zurich-Schlieren, Switzerland.

R. D. Staiger, MD has disclosed that she is a recipient of grant/research funding from the Olga Mayenfisch Foundation, Zurich, Switzerland, and her spouse/life partner (if any) has no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. All other authors, faculty, and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity.

Lippincott CME Institute has identified and resolved all conflicts of interest concerning this educational activity.

Reprints: Roxane D. Staiger, MD, Department of Visceral and Transplant Surgery, University Hospital of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland (e-mail: RoxaneDiane.Staiger@usz.ch).

**CME** Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

**Key Words:** spiradenocarcinoma, malignant spiradenoma, sweat gland tumor, skin adnexal tumor, review

(*Am J Dermatopathol* 2017;39:715–725)

## LEARNING OBJECTIVES

Spiradenocarcinomas are rare and potentially aggressive adnexal neoplasms evolving from benign spiradenomas. Due to their scarcity guidelines for the optimal treatment of these cancers have not been determined so far. This CME article is intended to call attention to the clinical presentation and pathological and immunohistological features of spiradenocarcinomas; it also provides recommendations for their diagnostics, treatment, and follow-up.

After participating in this CME activity participants should be able to:

1. Explain the role and application of medical imaging, surgical resection, adjuvant treatments, and follow-up for treatment of spiradenocarcinomas.
2. Describe the main histopathological and immunohistochemical features of spiradenocarcinoma for diagnostics and prognostics.
3. Name possible preventive measures.

## INTRODUCTION

Spiradenocarcinomas (SCs), also referred to as malignant eccrine spiradenomas,<sup>1–3</sup> are rare malignant adnexal neoplasms arising from a benign spiradenoma of the eccrine sweat gland.<sup>1</sup> They are presumed to be highly aggressive. However, in the recent literature a more favorable clinical course in cases with low-grade histomorphological features has been reported.<sup>4–6</sup> The eccrine spiradenoma is considered the primary skin lesion from which an SC evolves, but de novo appearances have been reported as well.<sup>7–9</sup> Accelerated growth of a long-standing lesion, pain, and ulceration are the most common symptoms that lead to referral. Bluish discoloration and impairment resulting from tumor growth have also been described.<sup>3,10–12</sup> A connection to the Brooke–Spiegler Syndrome, an autosomal dominant genetic disorder, phenotypically characterized by multiple skin tumors, such as spiradenomas, cylindromas, trichoepitheliomas, and tumors of the parotid gland, is suspected.<sup>13–15</sup> The tumor suppressor gene *CYLD*, located on chromosome 16q12–q13 has been identified by genetic studies to encode for hereditary transmission of multiple familial cylindromas as well as its associated tumors arising from skin appendages and the parotid gland.<sup>16–18</sup>

One hundred twenty cases of SC have been published up to December 2015, most of them as case reports. Because

of its rarity the optimal treatment for SC is unclear. Our own difficulties with a patient with SC and the absence of guidelines for treatment have led to the objective to summarize the published data to find some guidance for diagnosis, treatment, and follow-up of SCs.

## LITERATURE REVIEW

### Materials and Methods

PubMed was searched for the key words “spiradenocarcinoma” (All Fields) and “malignant spiradenoma” (All Fields) up to December 31, 2015. This led to 151 matching results: 34 cases with the key word “spiradenocarcinoma” and 117 with “malignant spiradenoma.” Included in this review were reports with a histopathological diagnosis of SC, malignant spiradenoma, or with malignant differentiation of a spiradenoma. Reports of tumors consisting of a combination of different skin adnexal carcinomas (21), duplicate reports (11), and studies in which data concerning SCs could not be distinguished from other skin adnexal tumors (7) were excluded. One hundred twenty patients were presented in 71 case reports<sup>3,6–12,15–50,51–80</sup> and 3 case series.<sup>5,14,81</sup> Each case report was analyzed for patient’s age, sex, and ethnicity. Tumor characteristics were collected regarding size, location and duration of presence, symptoms as well as their existence until presentation. We extracted clinical data concerning treatment, staging, and histopathological features including immunohistochemical profile if available. Further, information on the clinical course, such as tumor recurrence, location of recurrence, time span between primary tumor and recurrence as well as its therapeutic approach was gathered. We added our own case to the analysis (Table 1).

## RESULTS

### Epidemiology and Clinical Findings

The epidemiology and clinical details of the published data is presented in Table 2. The median patient age was 60 years (range 8–92 years). SC occurred in 58 women (47.9%) to 44 men (36.3%). The ethnicity of the patient was rarely documented (17.3%). Tumor localization was equally distributed throughout the sweat gland carrying skin. The median tumor size at presentation was 3 cm (range 0.8–25 cm). Duration of presence of a previous lesion ranged from 2 months to 80 years (median 6.5 years). The most common tumor symptoms were growth acceleration, pain, and ulceration. Bluish discolorations and bleeding ulcers were also mentioned. In 5 cases the tumor mass caused impairment (ataxia, palsy, hearing loss, ptosis, or lymph edema) because of its size.<sup>8,11,12,19,55</sup> Duration of symptoms ranged from 1 week to 4 years (median 4 months).

### Diagnostics and Staging

Overall, diagnostic procedures and staging were poorly documented. The final diagnosis was based on the histopathological examination of an excisional biopsy or

**TABLE 1.** Case Report SC, Limmattal Hospital, Zurich-Schlieren, Switzerland

Case Report	
Patient	44 year old female, white
Tumor	Upper back Small lesion present since 15 yrs 50 × 80 × 40 mm
Clinical findings	Duration of symptoms: 1 mo Fast growing Ulceration Bluish discoloration
Preoperative examinations	Biopsy MRI Sonography breasts/axillary region Mammography PET/CT 320 MBq <sup>18</sup> F-FDG
Therapy	Radical tumor excision (10 mm margin) Bilateral axillary lymphnodectomy level I and II
Pathological features	Poorly differentiated spiradenocarcinoma, vascular invasion Surgical margins tumor free TNM classification pT2, V1, G3, R1. Small basophil cells with an isomorph nucleus, few mitotic figures Tubulo-glandular and hyalinized eosinophil stroma
Immunohistochemical features	CK 5/6, 7: positive (weak) EMA: positive p63 and p40 antibodies: positive (few) Expression of estrogen receptor: 10% of tumor cells (weak) C-KIT: positive; KIT mutation analysis: negative. TP53: pR273C mutation: 34%
Follow-Up	15 Mt. (death)
Recurrence and therapy	5 Mt. post initial surgery: 5 mm nodule upper lobe right lung → Wedge resection 12 Mt. pleural tumor mass growth through anterior right thorax wall into right mammary with rib arrosion → Palliative chemotherapy: Imatinib → Palliative radiotherapy of the bone metastases

CK, cytokeratin; C-KIT, tyrosine-protein kinase; EMA, epithelial membrane antigen; F-FDG, fludeoxyglucose; MBq, megabecquerel; TP53, tumor protein p53.

surgical resection specimen. Imaging procedures, including computed tomography (CT) scan (15/121), magnetic resonance imaging (MRI) (9/121), positron emission tomography-CT (PET-CT) (6/121), chest x-ray (4/121) and ultrasound (4/121), and scintigraphy of the lymphatic drainage (2/121) area were used for staging. Furthermore, one patient received a mammography, because of the tumor biopsy’s histological pattern’s similarity to mammary gland tissue.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

**TABLE 2.** Summary of Epidemiological and Clinical Information

Epidemiological and Clinical Information	Total Cases Available Data (% of Total Cases)	Recurrence-Free Survival (% of Total Cases)	Recurrence (% of Total Cases)	Death (% of Total Cases)
Total cases	121 (100)	45 (37.2)	21 (17.4)	13 (10.2)
Age (Median), yrs	60 (8–92)	63 (21–92)	59.5 (30–72)	70 (44–89)
Sex	102/121 (84.3)	43 (42.2)	18 (17.6)	12 (11.8)
Female	58/102 (56.9)	20 (35.5)	12 (20.7)	5 (8.6)
Male	44/102 (43.1)	23 (52.3)	6 (13.6)	7 (15.9)
Ethnicity, n (%)	21/121 (17.4)	8 (38.1)	5 (23.8)	3 (14.3)
White	12/21 (57.1)	6 (50.0)	2 (16.7)	2 (16.7)
African/African American	4/21 (19.0)	0 (0)	2 (50.0)	1 (25.0)
Asian	3/21 (14.3)	2 (66.7)	1 (33.3)	0 (0.0)
Indian	2/21 (9.5)	0 (0.0)	0 (0.0)	0 (0.0)
Tumor location	106/121 (87.6)	43 (60.6)	19 (17.9)	12 (11.3)
Head (face, scalp, neck)	39/106 (36.8)	13 (33.3)	8 (20.5)	8 (20.5)
Trunk (chest, back, abdomen, pelvis)	29/106 (27.4)	12 (41.4)	4 (13.8)	1 (3.4)
Extremities (incl. hand, foot)	38/106 (35.9)	18 (47.4)	5 (13.2)	1 (2.6)
Side of the body	41/121 (33.9)	22 (53.7)	6 (14.6)	1 (2.4)
Left	19/41 (46.3)	10 (52.6)	2 (10.5)	0 (0.0)
Right	22/41 (53.7)	12 (54.5)	4 (18.2)	1 (4.5)
Tumor size (Median), cm	3 (0.8–25)	3 (0.8–25)	4 (0.8–12)	5.5 (1–10)
Time lesion present before symptoms, yrs	0.17–80	8 (0.17–80)	9 (2–50)	4 (0.17–15)
≤2	20/66 (30.3)	9 (45.0)	1 (5.0)	2 (10.0)
>2	46/66 (69.7)	18 (39.1)	9 (19.6)	3 (6.5)
Symptoms	64/121 (52.9)	28 (43.8)	23 (35.9)	10 (15.6)
Growth	60/64 (93.8)	24 (40.0)	13 (21.7)	6 (10.0)
Pain	15/64 (23.4)	7 (46.7)	5 (33.3)	0 (0.0)
Ulceration	13/64 (20.3)	6 (46.2)	2 (15.4)	2 (15.4)
Bluish discoloration	4/64 (6.3)	1 (25.0)	1 (25.0)	0 (0.0)
Bleeding	4/64 (6.3)	2 (50.0)	1 (25.0)	1 (25.0)
Disabilities	5/64 (7.8)	1 (20.0)	1 (20.0)	1 (20.0)
Duration of symptoms	0.25 mo–4 yrs	8 mo (0.25 mo–4 yrs)	1 mo (1–23 mo)	2 mo (1–4 mo)

## Pathologic and Immunohistochemical Findings

Table 3 presents the pathological data. Tumor grading was reported in 30% (36/121) of all cases. As histopathologic criteria for such classification antigen KI-67 staining was reported in 58.3% (21 cases), mitotic rate in 36.1% (13 cases), and no statement was made in 5.5% (2 cases). Tumor grade was high in 19% (4/21) of cases with tumor recurrence and in 23% (3/13) of the patients who died during follow-up. Furthermore, a wide range of different immunohistochemical markers was tested. SCs are positive for most cytokeratins with CK 5–7 most frequently being reported. Also tumor protein p53 was found positive in 90% (28/31); estrogen receptors were rarely screened for with 63% being negative (5/8).

## Treatment

Tumor resection was the primary treatment for all patients; too advanced tumor progression for complete surgical resection was the only exception. Surgical excision of the afflicted lymphatic nodes was performed in 83% (10/12), in patients with extensive tumor spread a lymphnodectomy was refrained from. In addition to tumor resection, further treatment

was described in 6 case reports. Three patients received adjuvant radiotherapy,<sup>10,20,66</sup> one of them in combination with chemotherapy.<sup>62</sup> For the first patient no follow-up or outcome after radiotherapy was described.<sup>10</sup> For the second patient, a 6 months recurrent free survival after radiotherapy (dosage unknown) was reported.<sup>20</sup> In the third case a total dosage of 59.4 Gray (Gy) over 64 days onto the tumor bed was applied and 45 Gy over 35 days onto the inguinal and pelvic nodes. Tumor recurrence at the primary tumor location without distant metastases occurred 9 months later. Despite a wide tumor excision with lymphadenectomy and hyperthermic isolated limb perfusion chemotherapy lung metastases occurred 3 months later; the patient died 20 months after initial diagnosis.<sup>66</sup>

Four patients underwent adjuvant chemotherapy. The agents used were 5-FU,<sup>66</sup> Tamoxifen<sup>3</sup> Epirubicin,<sup>7</sup> and Ifosfamide.<sup>7</sup> The fourth patient was already under chemotherapy treatment because of an adenocarcinoma of the colon with liver metastases.<sup>70</sup> All patients were diagnosed with distant metastases or died within 4 months. The exception was, a patient treated with a continuous Tamoxifen therapy after tumor resection and lymphnodectomy of an estrogen receptor positive SC of the upper arm. No tumor recurrence was found after 41 months of follow-up.<sup>3</sup>

**TABLE 3.** Summary of Reported Pathologic and Immunohistochemical Findings

Pathologic and Immunohistochemical Findings	Total Cases Available Data (% of Total Cases)	Recurrence-Free Survival (% of Total Cases)	Recurrence (% of Total Cases)	Death (% of Total Cases)
Total cases	121 (100)	45 (37.2)	21 (17.4)	13 (10.2)
SC grading	36/121 (29.8)			
High	8/36 (22.2)	2 (25.0)	4 (50.0)	3 (37.5)
Low	28/36 (77.8)	21 (75.0)	4 (14.3)	4 (14.3)
Cytokeratins				
Positive	13/121 (10.7)	7 (53.8)	5 (38.5)	3 (23.1)
CK 5	3/121 (2.5)	2 (66.75)	1 (33.3)	1 (33.3)
CK 6	2/121 (1.7)	1 (50.0)	1 (50.0)	1 (50.0)
CK 7	7/121 (5.8)	3 (42.9)	4 (57.1)	3 (42.9)
Cytokeratin antibodies				
AE1	5/121 (4.1)	4 (80.0)	1 (20.0)	0 (0.0)
AE3	5/121 (4.1)	4 (80.0)	1 (20.0)	0 (0.0)
CAM 5.2	3/121 (2.5)	2 (66.75)	1 (33.3)	0 (0.0)
Proteins				
p53	28/121 (23.1)	23 (82.1)	2 (7.1)	4 (14.3)
Receptors				
Estrogen receptors	3/121 (2.5)	2 (66.75)	1 (33.3)	1 (33.3)
Progesterone receptor	1/121 (0.8)	1 (100)	0 (0.0)	0 (0.0)
Others				
MYB	2/121 (1.7)	1 (50)	0 (0.0)	1 (50.0)
c-KIT	1/121 (0.8)	0 (0)	1 (100)	1 (100)
EMA	13/121 (10.7)	10 (76.9)	2 (15.4)	2 (15.4)

c-KIT, tyrosine-protein kinase kit; EMA, epithelial membrane antigen.

**Outcome**

Oncological outcome is shown in Table 4. With a median follow-up time of 24 months, the total recurrent free survival was 37% (45/121), cases with tumor recurrence were reported in 17% (21/121), and the documented occurrence of death in 10% (13/121). The nodal status and local recurrence was rarely described. From the reported data, the median of 12 months follow-up time until tumor recurrence (range 1 month–7 years) was calculated. Those patients had tumor free resection margins in 67% (6/9); of the ones who died during follow-up R0 resection was described in 40% (2/5). Lung, bone, and lymph nodes were the most frequently reported locations of metastatic spread. Few cases of liver-, kidney-, and breast metastases have also been documented. Of the 13 deaths during follow-up, 3 patients died shortly after the surgery (1–8 weeks) and 5 showed tumor recurrence before death (recurrence 5–84 months).

**DISCUSSION**

The first case of an SC was reported in 1971 by Dabska.<sup>30</sup> Because of the low incidence of SC only few case series are available, each with less than 20 patients.<sup>5,14,81</sup> This results in a great variability of published data and makes a meaningful statistical analysis of the gathered information impossible.

The epidemiological features of SC are unspecific. SC occur predominately in the elderly patient (median age 60 years), however a wide range in patient age has been reported

throughout the literature (8–92 years).<sup>53,72</sup> There is no specific sex distribution of SC.<sup>8,15,81</sup> Our data summary do not support the suspicion of a predominance of the tumor localization in the head, neck, and trunk region that was suggested in previous reports.<sup>14,66,81</sup> The large sized carcinomas (>10 cm) main symptom was painless growth; therefore, medical consultation may have been delayed, allowing the tumor to reach such an extent. A lesion was often present for many years, before rapid growth, sometimes in combination with pain, ulceration, or less common, bleeding or discoloration occurred.<sup>14,15,44</sup> Therefore, we recommend the preventive excision of every diagnosed spiradenoma.

Preoperative investigations were rarely documented and consisted mostly of CT scans or MRI for determination of the extent of tumor infiltration. The few authors who added a PET/CT scan to their staging procedure<sup>3,10,28,53,60</sup> describe a notable gain of valuable information regarding the presence and location of metastases, especially if clinical findings were unremarkable. Fludeoxyglucose (FDG) PET/CT imaging is known to have high sensitivity for detection of metastases of skin tumors,<sup>82,83</sup> particularly for primary apocrine sweat gland carcinomas and eccrine porocarcinomas.<sup>84,85</sup> The proportion of FDG sensitive SC is unknown.


Not only was the follow-up period mostly brief, also further treatments and course of illness were barely reported once a recurrence occurred. Specific tumor markers have not been identified yet. The impact of tumor free resection margins regarding tumor recurrence or survival is unclear.<sup>2,66,81</sup> Our data, however, show fewer recurrences and deaths after tumor

**TABLE 4.** Outcome Summary

Outcome	Total Cases Available Data (% of Total Cases)	Recurrence-Free Survival (% of Total Cases)	Recurrence (% of Total Cases)	Death (% of Total Cases)
Total cases	121 (100)	45 (37.2)	21 (17.4)	13 (10.2)
Follow-up time (Median), mo	24	24	10	15
Resection margins	33/121 (27.3)			
R0 resection	26/33 (78.8)	18 (69.2)	6 (23.1)	2 (7.7)
R1 resection	7/33 (21.2)	1 (14.3)	3 (42.9)	3 (42.9)
Lymph node status	26/121 (21.5)			
Positive lymph nodes	13/26 (50)	7 (53.8)	4 (30.8)	2 (15.4)
Negative lymph nodes	13/26 (50)	11 (84.6)	2 (15.4)	0 (0.0)
Metastatic spread	23/121 (19.0)			
Lung	8/23 (34.8)			
Bone	6/23 (26.1)			
Lymphatic drainage	5/23 (21.7)			
Liver	2/23 (8.7)			
Kidney	1/23 (4.3)			
Breast	1/23 (4.3)			
Recurrence location	21/121 (17.3)			
Tumor bed	5/21 (23.8)			
Other location	11/21 (52.4)			
Death	13/121 (10.7)			
w/recurrence	5/13 (38.5)			
w/o recurrence	8/13 (61.5)			

R0 resection, tumor free resection margins; R1 resection, tumor reaches resection margins; w/, with; w/o, without.


resection with tumor free margins compared with R1 resections (recurrence 23% vs. 43%), (death 8% vs. 43%). Regional lymph node excision has been recommended for tumor



**FIGURE 1.** Overview: Squamous cell epithelial layer, sub-epithelial area with high-grade SC, underneath a defined zone with features of a spiradenoma. Case of an SC of a 44-year-old white woman, Limmattal Hospital, Zurich-Schlieren, Switzerland (Table 1).

positive regional lymph nodes<sup>2,3</sup> and sentinel node biopsy is considered useful in clinically unsuspecting ones.<sup>2</sup> However, the benefit of routine locoregional lymph node dissection is unknown and therefore not advised.<sup>66,81</sup> Our recommendation for radiological SC diagnostics and staging include MRI for defining the tumor extent and FDG PET/CT for the detection of metastases. For treatment, we strongly advice to obtain tumor free resection margins and recommend the resection of tumor positive lymph nodes. Follow-up should include recurrent imaging; frequency may be broadened over time.

Per definition, for the diagnosis of an SC areas of benign spiradenoma must be found adjacent to the malign transformation in the pathological examinations<sup>1</sup> (Fig. 1). The current WHO classification describes 2 major histologic patterns; one shows a continuous transformation from benign to malignant neoplasm, in the other the malignant transitions are adjacent to the spiradenoma without structural or cytological changes<sup>1</sup> (Fig. 2). De novo appearances of SC have been described<sup>7-9</sup>; they are an explicit rarity, because the malignant degeneration would need to be concurrent with the primary growth of the spiradenoma. Further, an interrelation between spiradenoma, cylindroma, and spiradenocylindroma has also been reported.<sup>4,86</sup> In the 2009, published case series on adnexal skin tumors,<sup>4</sup> 4 histomorphological patterns and their correlation with clinical behavior and prognosis were described: salivary gland type basal cell adenocarcinoma-like pattern low-grade (BCAC), salivary gland type BCAC high-grade, invasive adenocarcinoma not otherwise specified, and sarcomatoid (metaplastic) carcinoma. Considering the long-term-survival rates of 50% for skin adnexal tumors with



**FIGURE 2.** Magnification: Well-differentiated spiradenoma at the bottom featuring an abrupt transition to a high-grade SC with numerous atypical mitotic figures (WHO classification 2). Case of an SC of a 44-year-old white woman, Limmattal Hospital, Zurich-Schlieren, Switzerland (Table 1).

the histomorphological pattern of BCAC high-grade reported in this study, these neoplasms seem to be more aggressive compared with the BCAC low-grade type (100% long-term survival).<sup>4,14</sup> Also invasive adenocarcinoma not otherwise specified carcinomas are considered highly malignant neoplasms with rather poor outcomes, whereas sarcomatoid carcinomas show a relatively good survival.<sup>4</sup> However, this histopathologic classification for skin adnexal tumors is not commonly used yet.

Only in 30% of the published SC cases a tumor grade is declared; most of them being low-grade carcinomas (28 vs. 8 cases). Corresponding with previous findings, our data show a higher incidence regarding tumor recurrence and death in high-grade carcinomas (recurrence 50% vs. 14%, death 38% vs. 14%) compared with reported low-grade SC (Table 3).<sup>4,5,14</sup> Some SC feature spindle cells, giving a sarcomatoid appearance to the neoplasm<sup>4</sup>; however, mostly these tumors lack distinctive morphological features and hold no specific immunological profile. SCs are positive for most cytokeratins; also estrogen and progesterone receptor expression are occasionally found, presumably because of the common embryologic origin of eccrine sweat glands and mammary gland tissue.<sup>9</sup> Mutations in the TP53 gene is a known indicator for malignant transformation,<sup>87</sup> however, there is no obvious correlation between the TP53 mutation status and the p53 tumor suppressor protein expression.<sup>88</sup> Although strong p53 expression has been reported for SC,<sup>87</sup> these tumors typically lack mutations in the TP53 gene.<sup>5</sup> Furthermore, immunohistochemical staining for p53 appears to be heterogeneous; therefore, it cannot be reliably applied for identification of malignant transformed areas.<sup>5,88</sup> One recent case series analyzed 19 SC cases for myeloblastosis protein (MYB),<sup>5</sup> a proto-oncogene protein that plays an important role in proliferation, apoptosis, and differentiation of cells.<sup>89</sup> Although detected in spiradenomas, MYB is absent in its malignant transformation, regardless if high or low grade. Therefore it may serve as an additional immunohistochemical marker for the distinction between spiradenoma and its low-grade malignant transformation.<sup>5,90</sup> Our

recommendations for pathologic evaluations of a suspected SC are first, the verification of SC according to the 2 major histologic patterns,<sup>1</sup> second, the determination of the tumor differentiation grade for a more accurate estimation of the patient's prognosis and third, MYB staining for determination of malignant differentiation of a spiradenoma by histomorphologic uncertainty.

No data on the optimal management strategy concerning distant metastases or on a satisfactory response of radiotherapy or chemotherapy has been published.<sup>3,14,41,53</sup> There are known cases of adenoid cystic carcinomas, a type of malignant sweat gland tumor, responding to chemotherapy with Imatinib.<sup>91,92</sup> This protein kinase inhibitor targets c-KIT, which is expressed in a variety of malignant tumors, such as gastrointestinal stromal tumor, malignant melanoma or adenoid cystic carcinoma of the salivary gland.<sup>86,93</sup> A recent study further investigated benign and malignant sweat gland tumors according to their c-KIT expression.<sup>86</sup> Although immunohistochemical positivity to c-KIT was present in most analyzed sweat gland tumors, only the adenoid cystic carcinomas showed a population of c-KIT positive cells big enough for a useful Imatinib therapy.<sup>86</sup> Furthermore, Tamoxifen, a selective estrogen receptor modulator, has been tried as an adjuvant therapy in a case of estrogen receptor positive SC.<sup>3</sup> No tumor recurrence was stated for 41 months.<sup>3</sup> Because of the common embryologic tissue origin,<sup>9</sup> estrogen receptors may not only be found in mammary carcinomas, but also in rare cases of SC.

Radiotherapy of the tumor site has been recommended in the past<sup>36,74,79</sup> but was hardly performed in the literature. A literature review from 1986 has declared sweat gland tumors to be radioresistant, consequently little significance was granted to radiotherapy as treatment of such carcinomas.<sup>94</sup> Therefore, Tamoxifen therapy for those rare cases of estrogen receptor positive SC is the only useful recommendation regarding adjuvant therapy.

## CONCLUSION

Inferred from the available data, suspicion of a SC should lead to performance of an MRI for defining tumor extent and FDG PET/CT for detection of metastases. The main pillar of treatment is radical tumor excision and the resection of tumor involved regional lymph nodes. Histopathological evaluation should involve determination of tumor differentiation grade for prognosis estimation; high-grade carcinomas seem to have a much more aggressive behavior compared with low-grade SC, which carry the potential for cure. To evaluate the possibility of an adjuvant Tamoxifen therapy, staining for estrogen receptors is recommended. Excision of distant metastases has no therapeutic value, but may be done for symptom alleviation. Follow-up needs to be carried out in short intervals with frequent imaging. To assess the influence of each clinical, radiological, or histopathological parameter regarding patient's outcome, a prospective uniform international data collection would be required.

## REFERENCES

1. LeBoit PE, Burg G, Weedon D, et al. *Pathology & Genetics Skin Tumours*. Lyon, France: IARC Press; 2006.

2. Andreoli MT, Itani KM. Malignant eccrine spiradenoma: a meta-analysis of reported cases. *Am J Surg*. 2011;201:695–699.
3. Mirza I, Kloss R, Sieber SC. Malignant eccrine spiradenoma. *Arch Pathol Lab Med*. 2002;126:591–594.
4. Kazakov DV, Zelger B, Rutten A, et al. Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome. *Am J Surg Pathol*. 2009;33:705–719.
5. van der Horst MP, Marusic Z, Hornick JL, et al. Morphologically low-grade spiradenocarcinoma: a clinicopathologic study of 19 cases with emphasis on outcome and MYB expression. *Mod Pathol*. 2015;28:944–953.
6. Nyame TT, Mattos D, Lian CG, et al. Malignant eccrine spiradenoma of the face. *J Craniofac Surg*. 2015;26:1711–1712.
7. Chou SC, Lin SL, Tseng HH. Malignant eccrine spiradenoma: a case report with pulmonary metastasis. *Pathol Int*. 2004;54:208–212.
8. Meyer TK, Rhee JS, Smith MM, et al. External auditory canal eccrine spiradenocarcinoma: a case report and review of literature. *Head Neck*. 2003;25:505–510.
9. Ribeiro-Silva A, Shaletich C, Careta RS, et al. Spiradenocarcinoma of the breast arising in a long-standing spiradenoma. *Ann Diagn Pathol*. 2004;8:162–166.
10. Gingrich AA, Fung MA, Konia T, et al. Locally advanced spiradenocarcinoma in the regional axilla of a breast cancer patient: hallmarks of definitive diagnosis and management. *Rare Tumors*. 2015;7:5912.
11. Chetty R, Perez-Ordóñez B, Gilbert R, et al. Spiradenocarcinoma arising from a spiradenocylindroma: unusual case with lymphoepithelioma-like areas. *J Cutan Med Surg*. 2009;13:215–220.
12. Torrado CS, Gomez-Castro A, Outeirino E, et al. Spiradenocarcinoma of the eyelid: a case report. *Orbit*. 2011;30:189–191.
13. Chen M, Liu H, Fu X, et al. Brooke-Spiegler syndrome associated with cylindroma, trichoepithelioma and eccrine spiradenoma. *Int J Dermatol*. 2013;52:1602–1604.
14. Dai B, Kong YY, Cai X, et al. Spiradenocarcinoma, cylindrocarcinoma and spiradenocylindrocarcinoma: a clinicopathological study of nine cases. *Histopathology*. 2014;65:658–666.
15. Kazakov DV, Benkova K, Michal M, et al. Skin type spiradenoma of the parotid gland with malignant transformation: report of a case with analysis of the CYLD gene. *Hum Pathol*. 2009;40:1499–1503.
16. Rajan N, Burn J, Langtry J, et al. Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression. *J Pathol*. 2011;224:309–321.
17. Dubois A, Hodgson K, Rajan N. Understanding Inherited cylindromas: clinical implications of gene discovery. *Dermatol Clin*. 2017;35:61–71.
18. Aguilera CA, De la Varga Martinez R, Garcia LO, et al. Heterozygous cylindromatosis gene mutation c.1628\_1629delCT in a family with Brooke-Spiegler syndrome. *Indian J Dermatol*. 2016;61:580.
19. Agarwal S, Khanna R, Arya NC, et al. Malignant eccrine spiradenoma: an unusual presentation. *Indian J Dermatol Venereol Leprol*. 2002;68:290–291.
20. Arslan E, Unal S, Cinel L, et al. Malignant eccrine spiradenoma occurring on a traumatized area. *Plast Reconstr Surg*. 2002;110:365–367.
21. Ascari J, Boaventura MA, Takahashi JA, et al. Biotransformation of bioactive isocaryolanes by *Botrytis cinerea*. *J Nat Prod*. 2011;74:1707–1712.
22. Baker GM, Selim MA, Hoang MP. Vulvar adnexal lesions: a 32-year, single-institution review from Massachusetts General Hospital. *Arch Pathol Lab Med*. 2013;137:1237–1246.
23. Beekley AC, Brown TA, Porter C. Malignant eccrine spiradenoma: a previously unreported presentation and review of the literature. *Am Surg*. 1999;65:236–240.
24. Ben Brahim E, Sfia M, Tangour M, et al. Malignant eccrine spiradenoma: a new case report. *J Cutan Pathol*. 2010;37:478–481.
25. Bercin S, Kutluhan A, Metin A, et al. Malignant eccrine spiradenoma on the lateral margin of nose as an infrequent localization. *Indian J Dermatol*. 2009;54:173–175.
26. Bicer YO, Koybasi S, Tezcan E, et al. Malignant eccrine spiradenoma of the external ear. *Kulak Burun Bogaz İhtis Derg*. 2015;25:245–248.
27. Braun-Falco M, Bonel H, Ring J, et al. Linear spiradenoma with focal malignant transformation. *J Eur Acad Dermatol Venereol*. 2003;17:308–312.
28. Chase DM, Basu T, Saffari B, et al. Malignant eccrine spiradenoma of the vulva: a case report and review of the literature. *Int J Gynecol Cancer*. 2006;16:1465–1469.
29. Chow W, Griffiths M. A malignant eccrine spiradenoma of the scalp. *BMJ Case Rep*. 2014;2014:1–3.
30. Dabska M. On malignant transformation of eccrine spiradenoma [in Polish]. *Nowotwory*. 1971;21:37–45.
31. de Andres Gomez A, Navarro Moratalla C, Villalba Ferrer F, et al. Malignant eccrine breast spiradenoma. A case report and literature review. *Int J Surg Case Rep*. 2015;15:81–84.
32. Delendi M, Puglisi F, Della Mea V, et al. Spiradenocarcinoma: morphological and immunohistochemical features. *Adv Clin Path*. 1997;1:287–291.
33. Delfino S, Toto V, Brunetti B, et al. Recurrent atypical eccrine spiradenoma of the forehead. *In Vivo*. 2008;22:821–823.
34. Dijkhuizen T, van den Berg E, Nikkels PG, et al. Cytogenetics of a case of eccrine spiradenoma. *Hum Pathol*. 1992;23:1085–1087.
35. Emam EE, Sawan AS, Al-Tamimi SR, et al. Malignant spiradenoma/cylindroma of the vulva. *Saudi Med J*. 2012;33:1229–1233.
36. Engel CJ, Meads GE, Joseph NG, et al. Eccrine spiradenoma: a report of malignant transformation. *Can J Surg*. 1991;34:477–480.
37. Grigoryan KV, Barlev D. Multiple fungating exophytic nodules secondary to metastatic spiradenocarcinoma with direct spinal cord invasion. *Int J Dermatol*. 2016;55:e552–e554.
38. Hantash BM, Chan JL, Egbert BM, et al. De novo malignant eccrine spiradenoma: a case report and review of the literature. *Dermatol Surg*. 2006;32:1189–1198.
39. Herzberg AJ, Elenitsas R, Strohmeier CR. An unusual case of early malignant transformation in a spiradenoma. *Dermatol Surg*. 1995;21:731–734.
40. Husek K, Plchova M, Samohyl J. Malignant transformation in multiple eccrine spiradenoma [in Czech]. *Cesk Patol*. 1992;28:48–52.
41. Ishikawa M, Nakanishi Y, Yamazaki N, et al. Malignant eccrine spiradenoma: a case report and review of the literature. *Dermatol Surg*. 2001;27:67–70.
42. Itoh T, Yamamoto N, Tokunaga M. Malignant eccrine spiradenoma with smooth muscle cell differentiation: histological and immunohistochemical study. *Pathol Int*. 1996;46:887–893.
43. Jamshidi M, Nowak MA, Chiu YT, et al. Giant malignant eccrine spiradenoma of the scalp. *Dermatol Surg*. 1999;25:45–48.
44. Jariwala A, Evans A, McLeod G. Not all stubbed toes are innocuous—A case report of rare malignant eccrine spiradenoma (spiradenocarcinoma) of the toe. *Foot Ankle Surg*. 2010;16:e32–e33.
45. Kaku Y, Fukumoto T, Kimura T. Spiradenocarcinoma in preexisting spiradenoma with a large in situ adenocarcinoma component. *Am J Dermatopathol*. 2015;37:e122–e125.
46. Kelly BT, Kadmas WR, Gayle L, et al. Extensor mechanism reconstruction after wide excision of a malignant eccrine spiradenocarcinoma of the patellar tendon. *J Knee Surg*. 2002;15:161–164.
47. Lee HH, Lee KG. Malignant eccrine spiradenoma with florid squamous differentiation. *J Korean Med Sci*. 1998;13:191–195.
48. Leonard N, Smith D, McNamara P. Low-grade malignant eccrine spiradenoma with systemic metastases. *Am J Dermatopathol*. 2003;25:253–255.
49. Mardi K, Sharma J. Malignant eccrine spiradenoma. *Indian J Pathol Microbiol*. 2007;50:36–37.
50. Matsuda M, Koguchi K, Takami Y, et al. A huge subcutaneous tumor occurring on the face (malignant eccrine spiradenoma)—histochemical and electron microscopy study [in Japanese]. *Nihon Hifuka Gakkai Zasshi*. 1987;97:117–124.
51. McCluggage WG, Fon LJ, O'Rourke D, et al. Malignant eccrine spiradenoma with carcinomatous and sarcomatous elements. *J Clin Pathol*. 1997;50:871–873.
52. Meriggi F, Tagliabo R, Morone G, et al. The potential malignancy of eccrine spiradenoma. *Ital J Surg Sci*. 1989;19:265–268.
53. Miedema JR, Burgon E, Burkhart C, et al. Metastatic spiradenocarcinoma occurring in an 8-year-old boy. *Pediatr Dermatol*. 2015;32:122–127.
54. Otero-García JE, Carlo VJ, Trinidad-Pinedo J. Malignant eccrine spiradenoma of the neck: a case report. *Otolaryngol Head Neck Surg*. 2001;125:428.
55. Pedamallu SB, Murphy J, Boyd D, et al. Direct intracranial extension of malignant eccrine spiradenoma of the face. *J Clin Med Res*. 2009;1:181–183.
56. Petersson F, Nga ME. Spiradenocarcinoma with low-grade basal cell adenocarcinoma pattern: report of a case with varied morphology and wild type TP53. *J Cutan Pathol*. 2012;39:372–376.

57. Roetman B, Vakilzadeh F, Krismann M. Eccrine spiradenocarcinoma with unusual histiocytic giant cell components. Case report and review of the literature of a rare sweat gland tumor [in German]. *Pathologie*. 2002;23:149–155.
58. Russ BW, Meffert J, Bernert R. Spiradenocarcinoma of the scalp. *Cutis*. 2002;69:455–458.
59. Saboorian MH, Kenny M, Ashfaq R, et al. Carcinosarcoma arising in eccrine spiradenoma of the breast. Report of a case and review of the literature. *Arch Pathol Lab Med*. 1996;120:501–504.
60. Schwarz D, Gobel H, Gostian AO, et al. Spiradenocarcinoma of the forehead: a rare skin tumor in the head and neck region [in German]. *HNO*. 2016;64:328–330.
61. Seyhan T, Borman H, Bal N. Malignant eccrine spiradenoma of the scalp. *J Craniofac Surg*. 2008;19:1608–1612.
62. Sobanko JF, Vanderbeek GE, White KP, et al. What is your diagnosis? *Spiradenocarcinoma Cutis*. 2013;92:285–287.
63. Sonmez Ergun S, Balsever Kural Y, Buyukbabani N. Guess what! Malignant eccrine spiradenoma. *Eur J Dermatol*. 2000;10:65–67.
64. Tanaka Y, Bhunchet E, Shibata T. A case of malignant eccrine spiradenoma metastatic to intramammary lymph node. *Breast Cancer*. 2008;15:175–180.
65. Tanese K, Sato T, Ishiko A. Malignant eccrine spiradenoma: case report and review of the literature, including 15 Japanese cases. *Clin Exp Dermatol*. 2010;35:51–55.
66. Tay JS, Tapen EM, Solari PG. Malignant eccrine spiradenoma. Case report and review of the literature. *Am J Clin Oncol*. 1997;20:552–557.
67. Thomas B, Duwel V, Proot L, et al. An uncommon breast tumour: the malignant eccrine spiradenoma. A case report. *Acta Chir Belg*. 1993;93:295–298.
68. Varsa EW, Jordan SW. Fine needle aspiration cytology of malignant spiradenoma arising in congenital eccrine spiradenoma. *Acta Cytol*. 1990;34:275–277.
69. Xu XL, Chen H, Song H, et al. A rare case of spiradenocarcinoma with features of adenoid cystic carcinoma. *Eur J Dermatol*. 2015;25:614–615.
70. Yildirim S, Akoz T, Akan M, et al. De novo malignant eccrine spiradenoma with an interesting and unusual location. *Dermatol Surg*. 2001;27:417–420.
71. Zamboni AC, Zamboni WA, Ross DS. Malignant eccrine spiradenoma of the hand. *J Surg Oncol*. 1990;43:131–133.
72. Fernandez-Acenero MJ, Manzarbeitia F, Mestre de Juan MJ, et al. Malignant spiradenoma: report of two cases and literature review. *J Am Acad Dermatol*. 2001;44(2 suppl):395–398.
73. Argenyi ZB, Nguyen AV, Balogh K, et al. Malignant eccrine spiradenoma. A clinicopathologic study. *Am J Dermatopathol*. 1992;14:381–390.
74. Wick MR, Swanson PE, Kaye VN, et al. Sweat gland carcinoma ex eccrine spiradenoma. *Am J Dermatopathol*. 1987;9:90–98.
75. Yaremchuk MJ, Elias LS, Graham RR, et al. Sweat gland carcinoma of the hand: two cases of malignant eccrine spiradenoma. *J Hand Surg Am*. 1984;9:910–914.
76. Mambo NC. Eccrine spiradenoma: clinical and pathologic study of 49 tumors. *J Cutan Pathol*. 1983;10:312–320.
77. Evans HL, Su D, Smith JL, et al. Carcinoma arising in eccrine spiradenoma. *Cancer*. 1979;43:1881–1884.
78. Cooper PH, Frierson HF Jr, Morrison AG. Malignant transformation of eccrine spiradenoma. *Arch Dermatol*. 1985;121:1445–1448.
79. Biernat W, Wozniak L. Spiradenocarcinoma: a clinicopathologic and immunohistochemical study of three cases. *Am J Dermatopathol*. 1994;16:377–382.
80. Galadari E, Mehregan AH, Lee KC. Malignant transformation of eccrine tumors. *J Cutan Pathol*. 1987;14:15–22.
81. Granter SR, Seeger K, Calonje E, et al. Malignant eccrine spiradenoma (spiradenocarcinoma): a clinicopathologic study of 12 cases. *Am J Dermatopathol*. 2000;22:97–103.
82. Charest M, Hickeyson M, Lisbona R, et al. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. *Eur J Nucl Med Mol Imaging*. 2009;36:1944–1951.
83. Holder WD Jr, White RL Jr, Zuger JH, et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. *Ann Surg*. 1998;227:764–769. discussion 769–771.
84. Singh H, Sharma P, Suman Kc S, et al. Apocrine sweat gland carcinoma: initial evaluation, staging, and response monitoring using 18F-FDG PET/CT. *Clin Nucl Med*. 2013;38:e223–e225.
85. Li SH, Chen MT, Chen YJ, et al. Metastatic eccrine porocarcinoma detected on FDG PET/CT. *Clin Nucl Med*. 2007;32:743–745.
86. Nishida H, Daa T, Kashima K, et al. KIT (CD117) expression in benign and malignant sweat gland tumors. *Am J Dermatopathol*. 2015;37:898–905.
87. Biernat W, Kordek R, Wozniak L. Over-expression of p53 protein as an indicator of the malignant transformation in spiradenoma. *Histopathology*. 1995;26:439–443.
88. Kazakov DV, Grossmann P, Spagnolo DV, et al. Expression of p53 and TP53 mutational analysis in malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma, sporadic or associated with Brooke-Spiegler syndrome. *Am J Dermatopathol*. 2010;32:215–221.
89. Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. *Oncogene*. 1999;18:3017–3033.
90. Brill LB II, Kanner WA, Fehr A, et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. *Mod Pathol*. 2011;24:1169–1176.
91. Faivre S, Raymond E, Casiraghi O, et al. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. *J Clin Oncol*. 2005;23:6271–6273. author reply 6273–4.
92. Vila L, Liu H, Al-Quran SZ, et al. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. *Mod Pathol*. 2009;22:1296–1302.
93. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. *J Clin Oncol*. 2004;22:4514–4522.
94. Morris DM, Sanusi ID, Lanehart WH. Carcinoma of eccrine sweat gland: experience with chemotherapy, autopsy findings in a patient with metastatic eccrine carcinoma, and a review of the literature. *J Surg Oncol*. 1986;31:26–30.

## CME EXAM INSTRUCTIONS FOR OBTAINING AMA PRA CATEGORY 1 CREDITS™

The American Journal of Dermatopathology includes CME-certified content that is designed to meet the educational needs of its readers.

An annual total of 12 *AMA PRA Category 1 Credits*™ is available through the twelve 2017 issues of The American Journal of Dermatopathology. This activity is available for credit through September 28, 2018.

### *Accreditation Statement*

Lippincott Continuing Medical Education Institute, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### *Credit Designation Statement*

Lippincott Continuing Medical Education Institute, Inc., designates this journal-based CME activity for a maximum of one (1) *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To earn CME credit, you must read the article in The American Journal of Dermatopathology and complete the quiz, answering at least 80 percent of the questions correctly. Mail the Answer Sheet along with a check or money order for the \$15 processing fee, to Lippincott CME Institute, Inc., Wolters Kluwer Health, Two Commerce Square, 2001 Market Street, 3rd Floor, Philadelphia, PA 19103. Only the first entry will be considered for credit, and must be postmarked by the expiration date. Answer sheets will be graded and certificates will be mailed to each participant within 6 to 8 weeks of participation.

## CME EXAMINATION October 2017

Please mark your answers on the ANSWER SHEET.

After participating in this CME activity participants should be able to explain the role and application of medical imaging, surgical resection, adjuvant treatments, and follow-up for treatment of spiradenocarcinomas, describe the main histopathological and immunohistochemical features of spiradenocarcinoma for diagnostics and prognostics, name possible preventive measures.

1. Which statement regarding surgical treatment of spiradenocarcinomas is true?
  - a. Resection margin of 1 cm is imperative for prevention of local tumor recurrence
  - b. R0 resection (tumor free resection margins) is associated with lower tumor recurrence
  - c. Excision of tumor positive regional lymph nodes has no impact on the course of the disease
  - d. Resection of distant metastases decelerates disease progress
  
2. Which statement for diagnostics or nonsurgical treatment of spiradenocarcinomas is true?
  - a. Tumor staging should include PET/CT for diagnosis of metastases
  - b. Yearly clinical check ups are the current recommendations for follow-up after surgical resection of spiradenocarcinomas
  - c. The combination of chemotherapy and radiotherapy is a promising adjuvant therapy
  - d. Neoadjuvant Tamoxifen therapy increases recurrent free survival rate
  
3. Which statement of the pathological features of spiradenocarcinomas is true?
  - a. The histologic pattern of a spiradenocarcinoma always shows a continuous transformation from benign to malignant neoplasm
  - b. Spiradenocarcinoma have distinctive morphological features
  - c. The quantity of atypical mitotic figures has no influence on the prognosis
  - d. Essential for the diagnosis of spiradenocarcinoma a part of benign spiradenoma must be found adjacent to the area of malign transformation

4. All of the following pathological or immunohistological findings can be detected in spiradenocarcinomas. Which of them has the greatest significance for prognostics?
- p53 tumor suppressor protein expression
  - Mitotic figure count
  - Presence of estrogen/progesterone receptors
  - MYB staining
5. Which of the following approaches is the most promising preventive measure for spiradenocarcinomas?
- Frequent clinical follow-up of diagnosed spiradenomas
  - Preventive Tamoxifen therapy
  - Preventive excision of ascertained spiradenomas
  - No preventive measure can be taken

**ANSWER SHEET FOR THE AMERICAN JOURNAL OF DERMATOPATHOLOGY  
CME PROGRAM EXAM  
October 2017**

Please answer the questions on page 723 by filling in the appropriate circles on the answer sheet below. Please mark the one best answer and fill in the circle until the letter is no longer visible. To process your exam, you must also provide the following information:

Name (please print): \_\_\_\_\_  
 Street Address \_\_\_\_\_  
 City/State/Zip \_\_\_\_\_  
 Daytime Phone \_\_\_\_\_  
 Specialty \_\_\_\_\_

- 1.  A  B  C  D  E
- 2.  A  B  C  D  E
- 3.  A  B  C  D  E
- 4.  A  B  C  D  E
- 5.  A  B  C  D  E

Your evaluation of this CME activity will help guide future planning. Please respond to the following questions below.

Please rate these activities (1 — minimally, 5 — completely) 1 2 3 4 5  
 These activities were effective in meeting the educational objectives       
 These activities were appropriately evidence-based       
 These activities were relevant to my practice

Please rate your ability to achieve the following objectives, both before and after this activity: 1 (minimally) to 5 (completely)

	Pre					Post				
	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>
After participating in this CME activity participants should be able to:										
1. Explain the role and application of medical imaging, surgical resection, adjuvant treatments, and follow-up fortreatment of spiradenocarcinomas	<input type="radio"/>									
2. Describe the main histopathological and immunohistochemical features of spiradenocarcinoma for diagnostics and prognostics	<input type="radio"/>									
3. Name possible preventive measures	<input type="radio"/>									

Do you expect that these activities will help you improve your skill or judgment within the next 6 months? (1 — definitely will not change, 5 — definitely will change) 1 2 3 4 5

4. How many patients are likely to be impacted by what you learned from this activity?  
 <20%     20-40%     40-60%     60-80%     >80%

5. Please list at least one (1) change you will make to your practice as a result of this activity: \_\_\_\_\_

6. How will you apply what you learned from these activities (mark all that apply):

- In diagnosing patients
- In monitoring patients
- In educating students and colleagues
- As part of the quality or performance improvement project
- For maintenance of board certification
- In making treatment decisions
- As a foundation to learn more
- In educating patients and their caregivers
- To confirm current practice
- For maintenance of licensure

7. How committed are you to applying this activity to your practice in the ways you indicated above? 1 2 3 4 5  
 (1 —definitely will not change, 5 — definitely will change)

8. Did you perceive any bias for or against any commercial products or devices? **Yes** **No**  
 If yes, please explain:

9. How long did it take you to complete these activities? \_\_\_\_\_hours \_\_\_\_\_minutes  
 What are your biggest clinical challenges related to dermatopathology?

[ ] Yes! I am interested in receiving future CME programs from Lippincott CME Institute! (Please place a check mark in the box)

Mail the completed Answer Sheet and a check or money order for the \$15 processing fee by September 28, 2018 to:  
 Lippincott CME Institute, Inc.  
 Wolters Kluwer Health  
 Two Commerce Square  
 2001 Market Street, 3rd Floor  
 Philadelphia, PA 19103